Last reviewed · How we verify
NCT06819280
Autologous Tumor-Infiltrating Lymphocyte (GT307) for Treatment of Patients With Advanced Colorectal Cancer
NA trial testing GT307 injection in Adult in 18 participants. Currently enrolling.
27 May 2027
Quick facts
| Lead sponsor | Grit Biotechnology |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 18 |
| Start date | 28 June 2024 |
| Primary completion | 27 May 2027 |
| Estimated completion | 27 May 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- GT307 injection — full drug profile →
Conditions studied
- Adult — all drugs for Adult →
Sponsor
Grit Biotechnology — full company profile →
Who can join
Adults 18 to 70, any sex, with Adult. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a single arm, open design aimed at evaluating the safety and tolerability of Autologous Tumor-Infiltrating Lymphocyte (GT307) for treatment of patients with Advanced Colorectal Cancer,while evaluating pharmacokinetic characteristics and efficacy assessment to determine the optimal biological dose (OBD).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
HosTIL territory: mapping the landscape of toxicity in TIL therapy.
Woodford R, Demiguelarroyo MJ, Jethra R, Lorigan PC, et al · · 2026 · PMID 41956543 · DOI 10.1136/jitc-2025-014378
Verify or expand the search:
- PubMed search for NCT06819280
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of GT307 injection
Trials testing the same drug.
- NCT07534813 — A Single-Arm Clinical Study of Autologous Tumor-Infiltrating Lymphocyte Injection (GT307) in the Treatment of Metastatic · NA · not yet recruiting
- NCT06453057 — Autologous Tumor-Infiltrating Lymphocyte (GT307) for Treatment of Patients With Solid Tumours · NA · recruiting
- NCT06397963 — Autologous Tumor-Infiltrating Lymphocyte (GT307 Injection ) for Treatment of Patients With Solid Tumours · NA · recruiting
Other recruiting trials for Adult
Currently open trials in the same condition.
- NCT07354607 — Effect of Transcutaneous Electrical Stimulation on Peripheral Blood Flow · NA · recruiting
- NCT07163728 — Leptin: A Marker for AML Chemo-Sensitivity · recruiting
- NCT07035171 — CABGpreHAB - a Feasibility Study Protocol · NA · recruiting
- NCT07018518 — PIN in Combination With Anti-PD1 in Previously Treated Primary Hepatocellular Carcinoma · Phase 1 · recruiting
- NCT06883149 — PIN in Combination With Anti-PD1 in Previously Treated Solid Tumor · Phase 1 · recruiting
Other Grit Biotechnology trials
Trials by the same sponsor.
- NCT07534813 — A Single-Arm Clinical Study of Autologous Tumor-Infiltrating Lymphocyte Injection (GT307) in the Treatment of Metastatic · NA · not yet recruiting
- NCT07389499 — A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediate · EARLY_PHASE1 · recruiting
- NCT07253259 — A Clinical Study Evaluating the Safety and Efficacy of GT729 Universal Cell Injection in the Treatment of Refractory or · EARLY_PHASE1 · recruiting
- NCT07333118 — A Clinical Study to Evaluate the Safety and Efficacy of GT801 Injection in the Treatment of Moderate-to-Severe Refractor · EARLY_PHASE1 · recruiting
- NCT07205315 — A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-p · EARLY_PHASE1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06819280 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Grit Biotechnology
- Last refreshed: 14 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06819280.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing